Clinical Trial Update: TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients [Phase 2]

View source ↗

Summary

Phase II randomized, placebo-controlled, dose-escalation trial of TMC125 (dapivirine) in HIV-1 infected patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC125 (dapivirine) (dapivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Anti-Retroviral Agents, HIV-1 | Phase 2 | Status: COMPLETED